Aspire Biopharma Holdings (ASBP) Preferred Stock Liabilities (2022 - 2024)
Aspire Biopharma Holdings (ASBP) posted quarterly Preferred Stock Liabilities of $6.7 million for Q4 2024, down 66.49% year-over-year from $19.9 million in Q1 2024, and up 2.21% quarter-over-quarter from $6.5 million in Q2 2024.
Aspire Biopharma Holdings (ASBP) Preferred Stock Liabilities (2022 - 2024) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Preferred Stock Liabilities for 3 consecutive years, with $6.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Preferred Stock Liabilities fell 66.49% year-over-year to $6.7 million; the TTM figure through Dec 2024 stood at $6.7 million (down 66.49% YoY), while the FY2024 annual figure was $6.7 million, down 66.49% from the prior year.
- Preferred Stock Liabilities improved to $6.7 million in Q4 2024 per ASBP's latest filing, from $6.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $302.2 million in Q1 2023 and bottomed at $6.5 million in Q2 2024.
- Historically, Preferred Stock Liabilities has averaged $143.7 million across 3 years, with a median of $20.1 million in 2024.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 2.55% in 2023 and fell as far as 93.37% in 2023.
- Aspire Biopharma Holdings' Preferred Stock Liabilities stood at $299.0 million in 2022, then tumbled by 93.34% to $19.9 million in 2023, then slumped by 66.49% to $6.7 million in 2024.
- Business Quant data shows ASBP's Preferred Stock Liabilities at $6.7 million in Q4 2024, $6.5 million in Q2 2024, and $20.1 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.67 Mn |
| Jun 30, 2024 | 6.52 Mn |
| Mar 31, 2024 | 20.14 Mn |
| Dec 31, 2023 | 19.90 Mn |
| Sep 30, 2023 | 19.64 Mn |
| Jun 30, 2023 | 20.02 Mn |
| Mar 31, 2023 | 302.20 Mn |
| Dec 31, 2022 | 299.00 Mn |
| Sep 30, 2022 | 296.46 Mn |
| Jun 30, 2022 | 295.13 Mn |
| Mar 31, 2022 | 294.69 Mn |